Rob
@bulmani.bsky.social
Data Scientist working in the UK in the education sector - interest in health, especially Lp(a) research, due to being in the 20% with high Lp(a)
A quick meta analysis of current lipid management therapies effect on LP(a) #lpa levels, and a call for more research on their effects on MACE/CVD outcomes pubmed.ncbi.nlm.nih.gov/40618457/
Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials - PubMed
Among available LLTs, PCSK9mAbs, inclisiran, CETPi, and niacin significantly decreased Lp(a) levels. Further research is necessary to understand whether this effect would translate into a clinically r...
pubmed.ncbi.nlm.nih.gov
July 10, 2025 at 1:09 PM
A quick meta analysis of current lipid management therapies effect on LP(a) #lpa levels, and a call for more research on their effects on MACE/CVD outcomes pubmed.ncbi.nlm.nih.gov/40618457/
Large study on LP(a) #lpa levels, likelihood of ASCVD events and impact of LDL lowering on events - thank you @familyheartfdn.bsky.social much to take in academic.oup.com/eurheartj/ad...
Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database
AbstractBackground and Aims. Higher levels of lipoprotein(a) drive increasing risk of atherosclerotic cardiovascular disease (ASCVD) in otherwise healthy i
academic.oup.com
May 11, 2025 at 8:20 AM
Large study on LP(a) #lpa levels, likelihood of ASCVD events and impact of LDL lowering on events - thank you @familyheartfdn.bsky.social much to take in academic.oup.com/eurheartj/ad...
Excellent large study on the increased risk of ASCVD with increasing levels of LP(a) #lpa with evidence of mitigation by aggressive LDL lowering treatment, in particular with PCSK9 inhibitors academic.oup.com/eurheartj/ad...
Validate User
academic.oup.com
May 7, 2025 at 5:57 PM
Excellent large study on the increased risk of ASCVD with increasing levels of LP(a) #lpa with evidence of mitigation by aggressive LDL lowering treatment, in particular with PCSK9 inhibitors academic.oup.com/eurheartj/ad...
An interesting study into CAC progression and associations with different levels of LP(a) which showed that LP(a) levels are not associated with CAC progress. Quite a powerful study with over 41,000 subjects #lpa academic.oup.com/eurjpc/advan...
Elevated lipoprotein(a) is not linked to coronary artery calcification incidence or progression
AbstractAims. Lipoprotein(a) [Lp(a)] is a genetically determined, independent risk factor for atherosclerotic cardiovascular disease. However, its role in
academic.oup.com
April 5, 2025 at 12:55 PM
An interesting study into CAC progression and associations with different levels of LP(a) which showed that LP(a) levels are not associated with CAC progress. Quite a powerful study with over 41,000 subjects #lpa academic.oup.com/eurjpc/advan...
Lepodisiran, Eli Lily's (phase 2 trial results for a) LP(a) lowering drug ALPACA trial results show a 94% reductions in LP(a) #lpa 500+ days on with 2 injection split times process shows high reduction remains. Shows promise as a once a year shot treatment www.acc.org/Latest-in-Ca...
ALPACA: Single Injection of Novel Lepodisiran Reduces Lp(a) Concentration - American College of Cardiology
www.acc.org
March 31, 2025 at 7:17 AM
Lepodisiran, Eli Lily's (phase 2 trial results for a) LP(a) lowering drug ALPACA trial results show a 94% reductions in LP(a) #lpa 500+ days on with 2 injection split times process shows high reduction remains. Shows promise as a once a year shot treatment www.acc.org/Latest-in-Ca...
A great watch and summarisation of LP(a) from Alberto Lorenzatti via the excellent @monteheart.bsky.social lectures youtube.com/live/q1ziJBr...
Lp(a) The hidden enemy? with Alberto Lorenzatti, MD
YouTube video by MonteHeart Lectures
youtube.com
March 29, 2025 at 6:47 PM
A great watch and summarisation of LP(a) from Alberto Lorenzatti via the excellent @monteheart.bsky.social lectures youtube.com/live/q1ziJBr...
Interesting piece of research, that indicates that higher levels of LP(a) are associated with less prevalence of NAFLD alongside other markers (e.g. hypertension) #lpa www.nature.com/articles/s41...
There is a linear negative correlation between lipoprotein(a) and non-alcoholic fatty liver disease - Scientific Reports
Scientific Reports - There is a linear negative correlation between lipoprotein(a) and non-alcoholic fatty liver disease
www.nature.com
March 13, 2025 at 8:10 AM
Interesting piece of research, that indicates that higher levels of LP(a) are associated with less prevalence of NAFLD alongside other markers (e.g. hypertension) #lpa www.nature.com/articles/s41...
Among atherosclerotic patients with and without T2DM, elevated Lp(a) level was significantly associated with a higher risk of MACE. Compared to those without T2DM, the patients with T2DM showed an excess MACE risk #lpa both risks need treatment especially when combo academic.oup.com/eurjpc/advan...
Impact of diabetes on risk of major adverse cardiovascular events associated with lipoprotein(a) levels in patients with established atherosclerotic cardiovascular disease
AbstractAims. Lipoprotein(a) [Lp(a)] is an emerging risk factor for major adverse cardiovascular events (MACE). However, evidence on MACE risk according to
academic.oup.com
March 13, 2025 at 7:53 AM
Among atherosclerotic patients with and without T2DM, elevated Lp(a) level was significantly associated with a higher risk of MACE. Compared to those without T2DM, the patients with T2DM showed an excess MACE risk #lpa both risks need treatment especially when combo academic.oup.com/eurjpc/advan...
Reposted by Rob
This JAMA Patient Page describes the risk factors, symptoms, diagnosis, and management of calcific aortic stenosis, which involves progressive narrowing and stiffening of the aortic valve. https://ja.ma/41xOEJr
February 27, 2025 at 9:00 PM
This JAMA Patient Page describes the risk factors, symptoms, diagnosis, and management of calcific aortic stenosis, which involves progressive narrowing and stiffening of the aortic valve. https://ja.ma/41xOEJr
Very poignant for me this paper, on a week where I have been rejected for preventative advice and support from NHS specialists. The outcome - the same (even though this is US data), a lack of knowledge about LP(a) and poor support from health care #LPA www.tandfonline.com/doi/full/10....
Living with Elevated Lipoprotein(a) Levels: The Experiences of Patients and Caregivers
Elevated lipoprotein(a) (Lp[a]) is an inherited condition that increases cardiovascular disease (CVD) risk, independent of other factors, such as low-density lipoprotein C. Few attempts have been m...
www.tandfonline.com
February 23, 2025 at 5:49 PM
Very poignant for me this paper, on a week where I have been rejected for preventative advice and support from NHS specialists. The outcome - the same (even though this is US data), a lack of knowledge about LP(a) and poor support from health care #LPA www.tandfonline.com/doi/full/10....
Treatment (US) recommendation graph in relation to the combination of high LP(a) #lpa levels and increasing CAC score. The combination of high LP(a) and high CAC score is a significant risk marker for CVD and should instigate a prompt response and activity www.researchgate.net/publication/...
www.researchgate.net
February 15, 2025 at 9:39 AM
Treatment (US) recommendation graph in relation to the combination of high LP(a) #lpa levels and increasing CAC score. The combination of high LP(a) and high CAC score is a significant risk marker for CVD and should instigate a prompt response and activity www.researchgate.net/publication/...
CRISPR tech lowering LP(a) #lpa 90% lowering with highest does, at least up to a year and counting www.pharmaceutical-technology.com/data-insight...
CTX-320 by CRISPR Therapeutics for Atherosclerosis: Likelihood of Approval
CTX-320 is under clinical development by CRISPR Therapeutics and currently in Phase I for Atherosclerosis.
www.pharmaceutical-technology.com
February 13, 2025 at 7:41 AM
CRISPR tech lowering LP(a) #lpa 90% lowering with highest does, at least up to a year and counting www.pharmaceutical-technology.com/data-insight...
This is a CVD calculator that I use when I get my blood results. It has a 2nd part once you press the calculate risk button to input your LP(a) levels and plots a new risk line. There is an option to plot a 3rd line against reductions of LDL-C & BP #lpa www.lpaclinicalguidance.com?fbclid=IwZXh...
Lp(a) Clinical Guidance
www.lpaclinicalguidance.com
February 9, 2025 at 9:48 AM
This is a CVD calculator that I use when I get my blood results. It has a 2nd part once you press the calculate risk button to input your LP(a) levels and plots a new risk line. There is an option to plot a 3rd line against reductions of LDL-C & BP #lpa www.lpaclinicalguidance.com?fbclid=IwZXh...
Back to November 24 for this research - output conclusions that managing ASCVD risk via LS7 score assessment irrespective of LP(a) level showed a reduction of ASCVD development academic.oup.com/eurjpc/advan...
Traditional risk factors, optimal cardiovascular health, and elevated lipoprotein(a)
AbstractAims. To assess the association of traditional risk factor burden and Life’s Simple 7 (LS7) score with incident atherosclerotic cardiovascular dise
academic.oup.com
February 8, 2025 at 6:23 PM
Back to November 24 for this research - output conclusions that managing ASCVD risk via LS7 score assessment irrespective of LP(a) level showed a reduction of ASCVD development academic.oup.com/eurjpc/advan...
LP(a) HORIZON outputs from Phase 3 trial confirmed as 2026 (was first scheduled for 2025), an event lead assessment, this will depend on the number of total events, so could move again, events depending #lpa here hopefull
February 2, 2025 at 6:12 PM
LP(a) HORIZON outputs from Phase 3 trial confirmed as 2026 (was first scheduled for 2025), an event lead assessment, this will depend on the number of total events, so could move again, events depending #lpa here hopefull
Meta analysis of PCSK9 inhibitors in LP(a) levels in those with high #lpa shows average of 27% reductions in LP(a) - calls for more analysis of whether the reductions resulted in better health outcomes and reductions of CVD events www.sciencedirect.com/science/arti...
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials
Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk.The authors examined the effect of monoclonal antibody pro…
www.sciencedirect.com
January 30, 2025 at 10:19 PM
Meta analysis of PCSK9 inhibitors in LP(a) levels in those with high #lpa shows average of 27% reductions in LP(a) - calls for more analysis of whether the reductions resulted in better health outcomes and reductions of CVD events www.sciencedirect.com/science/arti...
Examination of supine hypertension and CHD outcomes in @jama.com Really interesting insight, given technology in this space is getting better for 24 hour monitoring, this data and that tech, could a) save a lot lives b) improve the health of many jamanetwork.com/journals/jam...
Supine Blood Pressure and Risk of Cardiovascular Disease and Mortality
This cohort study investigates the association of supine hypertension with cardiovascular disease and mortality in middle-aged adults.
jamanetwork.com
January 27, 2025 at 11:57 AM
Examination of supine hypertension and CHD outcomes in @jama.com Really interesting insight, given technology in this space is getting better for 24 hour monitoring, this data and that tech, could a) save a lot lives b) improve the health of many jamanetwork.com/journals/jam...
I have this article locked in my archive of LP(a) articles, it is an easy read on the subject and again emphasizes the need for more research and data www.tctmd.com/news/high-lp...
High Lp(a) Levels Harmful in Patients With and Without ASCVD
(UPDATED) The threshold for increased risk differed, though, with only the highest Lp(a) levels conferring risk in secondary prevention.
www.tctmd.com
January 26, 2025 at 8:35 AM
I have this article locked in my archive of LP(a) articles, it is an easy read on the subject and again emphasizes the need for more research and data www.tctmd.com/news/high-lp...
Reasonable summary from 'Nature' on LP(a) good to get the profile on the subject matter and a readable introduction to the lipoprotein and further encouragement to people to get their levels checked with future treatments in the pipeline www.nature.com/research-int...
Lipoprotein(a) and Cardiovascular Disease Risk Factors | Nature Research Intelligence
Learn how Nature Research Intelligence gives you complete, forward-looking and trustworthy research insights to guide your research strategy.
www.nature.com
January 25, 2025 at 9:24 AM
Reasonable summary from 'Nature' on LP(a) good to get the profile on the subject matter and a readable introduction to the lipoprotein and further encouragement to people to get their levels checked with future treatments in the pipeline www.nature.com/research-int...
A good summary of the new LP(a) lowering medical trials, plus some individual stories and commentary on those trials and the people involved - hope remains www.webmd.com/cholesterol-...
New Drugs Offer Hope for People With High Lipoprotein(a) Cholesterol
There is no approved treatment for high lipoprotein(a), but five drugs are in development, and last fall, two of them moved a step closer to consideration by the FDA.
www.webmd.com
January 24, 2025 at 8:19 AM
A good summary of the new LP(a) lowering medical trials, plus some individual stories and commentary on those trials and the people involved - hope remains www.webmd.com/cholesterol-...
Great results from Phase 2 trial on Zerlasiran - providing hope that 2 jabs a year = significant reduction of Lp(a) Lipoprotein a, and safely. Plus added bonus of moderate ApoB reductions (see tables)
Zerlasiran, a small-interfering RNA, reduced time-averaged lipoprotein(a) concentrations by more than 80% during 36 weeks of treatment in patients with atherosclerotic cardiovascular disease.
https://ja.ma/4fv6ZdS
https://ja.ma/4fv6ZdS
January 21, 2025 at 4:20 PM
Great results from Phase 2 trial on Zerlasiran - providing hope that 2 jabs a year = significant reduction of Lp(a) Lipoprotein a, and safely. Plus added bonus of moderate ApoB reductions (see tables)
High Lp(a) levels among those with ASCVD than proportional large cohort in a Portuguese population - emphasizing the need for people to get this measure checked. My own observation that the general 28.7% with high levels was higher than expected (20%) lipidworld.biomedcentral.com/articles/10....
Prevalence of Lp(a) in a real-world Portuguese cohort: implications for cardiovascular risk assessment - Lipids in Health and Disease
Background Cardiovascular disease (CVD) is a major cause of mortality worldwide, necessitating more refined strategies for risk assessment. Recently, lipoprotein(a) [Lp(a)] has gained attention for it...
lipidworld.biomedcentral.com
January 21, 2025 at 9:46 AM
High Lp(a) levels among those with ASCVD than proportional large cohort in a Portuguese population - emphasizing the need for people to get this measure checked. My own observation that the general 28.7% with high levels was higher than expected (20%) lipidworld.biomedcentral.com/articles/10....
An interesting piece of research in the European Journal of Preventive Cardiology, assessing the association of risk factors, the 'Life's Simple 7' score with incident ASCVD across variable Lp(a) levels.
academic.oup.com/eurjpc/advan...
#Lpa #lipoproteinlittlea
academic.oup.com/eurjpc/advan...
#Lpa #lipoproteinlittlea
Traditional Risk Factors, Optimal Cardiovascular Health, and Elevated Lipoprotein(a)
AbstractAims. To assess the association of traditional risk factor burden and Life’s Simple 7 (LS7) score with incident atherosclerotic cardiovascular dise
academic.oup.com
November 30, 2024 at 9:12 PM
An interesting piece of research in the European Journal of Preventive Cardiology, assessing the association of risk factors, the 'Life's Simple 7' score with incident ASCVD across variable Lp(a) levels.
academic.oup.com/eurjpc/advan...
#Lpa #lipoproteinlittlea
academic.oup.com/eurjpc/advan...
#Lpa #lipoproteinlittlea
More research showing the benefits of exercise with regards to delaying the onset of dementia #dementia in the British Journal of Sports Medicine bjsm.bmj.com/content/earl...
Association of cardiorespiratory fitness with dementia risk across different levels of genetic predisposition: a large community-based longitudinal study
Objective We aimed to investigate the association of cardiorespiratory fitness (CRF) with cognitive function and dementia risk, taking genetic predisposition for dementia into account.
Methods Within...
bjsm.bmj.com
November 20, 2024 at 7:39 AM
More research showing the benefits of exercise with regards to delaying the onset of dementia #dementia in the British Journal of Sports Medicine bjsm.bmj.com/content/earl...
Interesting Lancet update regarding Dementia prevention www.thelancet.com/journals/lan...
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
The 2024 update of the Lancet Commission on dementia provides new hopeful evidence
about dementia prevention, intervention, and care. As people live longer, the number
of people who live with dementia...
www.thelancet.com
November 18, 2024 at 7:49 PM
Interesting Lancet update regarding Dementia prevention www.thelancet.com/journals/lan...